Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAsH-IV-AML: Hydroxyurea + Salvage Chemotherapy in R/R AML
NCT07766850Phase 2Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxyurea in acute myeloid leukemia (AML). Primary endpoint: 1-year Event-Free Survival. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
hydroxyurea
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07766850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07766850.